STOCK TITAN

Monthly information on share capital and company voting rights

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Cellectis (CLLS) has released its monthly share capital and voting rights information as of July 31, 2024, in compliance with French financial market regulations. The report indicates that the total number of shares in the capital is 100,093,635, while the total number of voting rights stands at 88,029,164. This information is important for investors to understand the company's ownership structure and potential voting power distribution.

The press release provides contact details for media and investor relations, including Pascalyne Wilson (Director of Communications) and Arthur Stril (Interim Chief Financial Officer). This transparency in reporting and accessibility to company representatives demonstrates Cellectis' commitment to maintaining open communication channels with stakeholders and complying with regulatory requirements.

Cellectis (CLLS) ha pubblicato le informazioni relative al capitale sociale e ai diritti di voto mensili al 31 luglio 2024, in conformità con le normative del mercato finanziario francese. Il rapporto indica che il numero totale di azioni in circolazione è di 100.093.635, mentre il numero totale di diritti di voto è di 88.029.164. Queste informazioni sono importanti per gli investitori per comprendere la struttura azionaria dell'azienda e la potenziale distribuzione del potere di voto.

Il comunicato stampa fornisce dettagli di contatto per i media e le relazioni con gli investitori, tra cui Pascalyne Wilson (Direttore delle Comunicazioni) e Arthur Stril (Chief Financial Officer ad interim). Questa trasparenza nella comunicazione e l'accessibilità ai rappresentanti dell'azienda dimostrano l'impegno di Cellectis a mantenere canali di comunicazione aperti con gli stakeholder e a rispettare i requisiti normativi.

Cellectis (CLLS) ha publicado su información mensual sobre el capital social y los derechos de voto a fecha del 31 de julio de 2024, cumpliendo con las regulaciones del mercado financiero francés. El informe indica que el número total de acciones en circulación es de 100.093.635, mientras que el número total de derechos de voto es de 88.029.164. Esta información es importante para que los inversores comprendan la estructura de propiedad de la empresa y la posible distribución del poder de voto.

El comunicado de prensa proporciona detalles de contacto para los medios y las relaciones con inversores, incluyendo a Pascalyne Wilson (Directora de Comunicaciones) y Arthur Stril (Director Financiero Interino). Esta transparencia en los informes y la accesibilidad a los representantes de la empresa demuestran el compromiso de Cellectis de mantener canales de comunicación abiertos con las partes interesadas y de cumplir con los requisitos regulatorios.

Cellectis (CLLS)는 2024년 7월 31일 기준으로 자본금 및 의결권에 대한 월간 정보를 발표했습니다. 이는 프랑스 금융 시장 규정을 준수한 것입니다. 보고서에 따르면 총 발행 주식 수는 100,093,635주이며, 총 의결권 수는 88,029,164권입니다. 이 정보는 투자자들이 회사의 소유 구조와 잠재적인 의결권 분배를 이해하는 데 중요합니다.

보도 자료는 언론 및 투자자 관계를 위한 연락처 정보도 제공하며, 여기에는 Pascalyne Wilson(커뮤니케이션 이사)과 Arthur Stril(임시 CFO)이 포함됩니다. 이러한 보고의 투명성과 회사 대표에 대한 접근 가능성은 Cellectis가 이해관계자와의 열린 소통 채널을 유지하고 규제 요구사항을 준수하려는 의지를 보여줍니다.

Cellectis (CLLS) a publié ses informations mensuelles concernant le capital social et les droits de vote au 31 juillet 2024, conformément aux réglementations du marché financier français. Le rapport indique que le nombre total d'actions en capital est de 100.093.635, tandis que le nombre total de droits de vote est de 88.029.164. Ces informations sont importantes pour les investisseurs afin de comprendre la structure de propriété de l'entreprise et la distribution potentielle des droits de vote.

Le communiqué de presse fournit les coordonnées pour les médias et les relations avec les investisseurs, y compris Pascalyne Wilson (Directrice de la Communication) et Arthur Stril (Directeur Financier par intérim). Cette transparence dans le reporting et l'accessibilité aux représentants de l'entreprise démontrent l'engagement de Cellectis à maintenir des canaux de communication ouverts avec les parties prenantes et à respecter les exigences réglementaires.

Cellectis (CLLS) hat am 31. Juli 2024 seine monatlichen Informationen zu Kapital und Stimmrechten veröffentlicht, um den französischen Finanzmarktregulierungen zu entsprechen. Der Bericht zeigt, dass die Gesamtzahl der Aktien 100.093.635 beträgt, während die Gesamtzahl der Stimmrechte 88.029.164 beträgt. Diese Informationen sind für Investoren wichtig, um die Eigentümerstruktur des Unternehmens und die mögliche Verteilung der Stimmrechte zu verstehen.

Die Pressemitteilung enthält Kontaktdaten für Medien und Investorenbeziehungen, darunter Pascalyne Wilson (Leiterin der Kommunikation) und Arthur Stril (Interim Chief Financial Officer). Diese Transparenz in der Berichterstattung und die Zugänglichkeit der Unternehmensvertreter zeigen das Engagement von Cellectis, offene Kommunikationskanäle zu den Interessengruppen aufrechtzuerhalten und die regulatorischen Anforderungen zu erfüllen.

Positive
  • Transparent reporting of share capital and voting rights information
  • Compliance with French financial market regulations
Negative
  • None.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Aug. 05, 2024 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares
in the capital
Total number of voting
rights
07/31/2024100,093,63588,029,164


For further information on Cellectis, please contact:
     

Media contact:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contacts:       

Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com 

 

Attachment


FAQ

What is the total number of shares in Cellectis (CLLS) capital as of July 31, 2024?

As of July 31, 2024, the total number of shares in Cellectis (CLLS) capital is 100,093,635.

How many voting rights does Cellectis (CLLS) have as of July 31, 2024?

Cellectis (CLLS) has 88,029,164 total voting rights as of July 31, 2024.

On which market are Cellectis (CLLS) shares listed?

Cellectis (CLLS) shares are listed on the Euronext Growth market.

What is the ISIN code for Cellectis (CLLS) stock?

The ISIN code for Cellectis (CLLS) stock is FR0010425595.

Cellectis S.A. American Depositary Shares

NASDAQ:CLLS

CLLS Rankings

CLLS Latest News

CLLS Stock Data

232.72M
72.09M
9.39%
14.77%
0.44%
Biotechnology
Healthcare
Link
United States of America
Paris